-
1 month ago | 
ascpt.onlinelibrary.wiley.com | Shirley Wang |Massimiliano Russo |Robert J Glynn |Marie Bradley
WHAT IS THE CURRENT KNOWLEDGE ON THIS TOPIC? Real-world evidence involving healthcare database studies is well established for making causal inferences in post-market drug safety studies and methods, data, and research infrastructure for evaluating effectiveness have advanced in recent years. WHAT QUESTION DID THIS STUDY ADDRESS?
-
Jul 16, 2024 | 
dom-pubs.onlinelibrary.wiley.com | Karine Suissa |Sebastian Schneeweiss |Robert J Glynn |Deborah J. Wexler
Samy Suissa PhD Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada Department of Medicine, McGill University, Montréal, Quebec, CanadaSearch for more papers by this author
-
Jun 24, 2024 | 
arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 | arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 | arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Feb 28, 2024 | 
onlinelibrary.wiley.com | Katsiaryna Bykov |Nazleen F Khan |Jeffrey N. Katz |Robert J Glynn
DATA AVAILABILITY STATEMENT N.F.K., S.M.V., and S.C.K. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
-
Oct 25, 2023 | 
onlinelibrary.wiley.com | Phyo T. Htoo |Robert J Glynn |Shirley Wang |Julie M. Paik
CONFLICT OF INTEREST STATEMENT Dr. Htoo was previously an employee of Johnson & Johnson on work unrelated to the submitted work. Dr. Schneeweiss reported receiving grants from Boehringer Ingelheim and personal fees from Aetion outside the submitted work. Dr. Glynn reported receiving grants from Amarin Corporation, Kowa Pharmaceuticals America, Novartis, and Pfizer outside the submitted work.
-
Apr 24, 2023 | 
mdpi.com | Camden P. Bay |Robert J Glynn |Johanna Seddon |Mei-Ling Ting Lee
Abstract:The area under the true ROC curve (AUC) is routinely used to determine how strongly a given model discriminates between the levels of a binary outcome. Standard inference with the AUC requires that outcomes be independent of each other.
-
Mar 20, 2023 | 
jamanetwork.com | Kueiyu Joshua Lin |Daniel E. Singer |Darae Ko |Robert J Glynn
Key PointsQuestion What is the association of frailty level with oral anticoagulant outcomes in terms of home time, clinical events, and total health care costs in patients with atrial fibrillation (AF)? Findings In this cohort study of 136 551 Medicare beneficiaries with AF, apixaban was associated with increased home time and fewer clinical events than rivaroxaban and warfarin, with greater differences among those with frailty.
-
Mar 6, 2023 | 00215-5/abstract&sz=64)
thelancet.com | Paul M. Ridker |Robert J Glynn |Jean G MacFadyen |Steven Nissen
Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
